Swedish Orphan Biovitrum AB - Company Profile
Powered by 
All the data and insights you need on Swedish Orphan Biovitrum AB in one report.
$295
- Save hours of research time and resources with
our up-to-date Swedish Orphan Biovitrum AB Strategy Report
- Understand Swedish Orphan Biovitrum AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation, and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS). Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.
Headquarters
Sweden
Address
Tomtebodavagen 23a, Solna, 17165
Website
www.sobi.com
Telephone
46 8 6972000
No of Employees
1,772
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SOBI (STO)
Revenue (2022)
$2.1B
17.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-8.7%
(2022 vs 2021)
Market Cap*
$8.2B
Net Profit Margin (2022)
XYZ
-22.5%
(2022 vs 2021)
* As of and is in US$
Swedish Orphan Biovitrum AB premium industry data and analytics
Products and Services
| Products |
|---|
| Hematology: |
| Elocta |
| Alprolix |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company and Handok Pharmaceuticals entered into a joint venture agreement for the commercialization and distribution of Sobi medicines in South Korea. |
| 2024 | Contracts/Agreements | In February, the company and Orexo entered into a collaboration to further the feasibility study with AmorphOX. |
| 2023 | Acquisitions/Mergers/Takeovers | In June, the company acquired CTI BioPharma for US$1.7 billion. |
Competitor Comparison
| Key Parameters | Swedish Orphan Biovitrum AB | BioGaia AB | New Nordic Healthbrands AB | Hansa Biopharma AB | Slottsviken Fastighetsaktiebolag |
|---|---|---|---|---|---|
| Headquarters | Sweden | Sweden | Sweden | Sweden | Sweden |
| City | Solna | Stockholm | Malmo | Lund | Goeteborg |
| No. of Employees | 1,772 | 210 | 73 | 168 | 1 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Annette Clancy | Chairman | Executive Board | 2024 | 70 |
| Guido Oelkers | Chief Executive Officer | Senior Management | 2017 | 58 |
| Henrik Stenqvist | Chief Financial Officer | Senior Management | 2018 | 56 |
| Lydia Abad-Franch | Head - Research, Development and Medical Affairs; Senior Vice President; Chief Medical Officer | Senior Management | 2023 | - |
| Christine Wesstrom | Head - Technical Operations | Senior Management | 2022 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward